GoodRx Holdings, Inc. (GDRX) Guidance & Earnings Results

On 2026-08-05 GoodRx Holdings, Inc. raised guidance: "FY2026 revenue $790-805M; Adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GDRXGoodRx Holdings, Inc.Follow GDRX — free

Information Technology Services · Technology

—

Price chart with a free account

Market cap: 1.2B
P/E TTM: 76.6
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	FY2026 revenue $790-805M; Adjusted EBITDA $240-250M · full year
6 May 26	Raised	FY2026 revenue raised to $765-785M from prior (not explicitly stated but implied raise); FY2026 Adjusted EBITDA >$235M (no prior range given). · full year
25 Feb 26	Lowered	FY2026 revenue $750-780M vs FY2025 $796.9M; Adjusted EBITDA >$230M · full year
4 Nov 25	Reaffirmed	FY2025 revenue: increase from 2024 ($792.3M); FY2025 Adjusted EBITDA: $265-$275M (vs $260.2M in FY2024, +2% to +6%); Pharma Manufacturer Solutions Revenue Outlook raised to ~35% YoY growth for 2025. · full year
6 Aug 25	Mixed	FY2025 revenue: increase from 2024 (FY2024 $792.3M); FY2025 Adjusted EBITDA: $265-275M (FY2024 $260.2M, 2-6% growth); Q3 revenue expected lower than Q4; Estimated revenue loss of $35-40M from Rite Aid bankruptcy and PBM program volume reduction · full year

GoodRx Holdings, Inc. — questions

What guidance did GoodRx Holdings, Inc. give?: On 2026-08-05: "FY2026 revenue $790-805M; Adjusted EBITDA $240-250M"
When does GoodRx Holdings, Inc. report earnings?: GoodRx Holdings, Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from GoodRx Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.